Sign in
4

Changes in Ownership

Beam Therapeutics Inc. Filed Acc 0000899243-21-027903

CEO sold 25,000 shares at an average $107.87 ($2,696,826)

  • CEO acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Evans John M. CEO 2021-07-07 Option exercise +25,000 $1.03 $25,750 1,046,525 D
Evans John M. CEO 2021-07-07 Sale −645 $100.69 $64,945 1,045,880 D
Evans John M. CEO 2021-07-07 Sale −2,300 $101.27 $232,921 1,043,580 D
Evans John M. CEO 2021-07-07 Sale −100 $102.00 $10,200 1,043,480 D
Evans John M. CEO 2021-07-07 Sale −2,864 $103.52 $296,481 1,040,616 D
Evans John M. CEO 2021-07-07 Sale −1,336 $104.40 $139,478 1,039,280 D
Evans John M. CEO 2021-07-07 Sale −1,800 $105.44 $189,792 1,037,480 D
Evans John M. CEO 2021-07-07 Sale −500 $106.48 $53,240 1,036,980 D
Evans John M. CEO 2021-07-07 Sale −167 $107.31 $17,921 1,036,813 D
Evans John M. CEO 2021-07-07 Sale −800 $108.65 $86,920 1,036,013 D
Evans John M. CEO 2021-07-07 Sale −4,800 $109.58 $525,984 1,031,213 D
Evans John M. CEO 2021-07-07 Sale −3,982 $110.54 $440,170 1,027,231 D
Evans John M. CEO 2021-07-07 Sale −3,456 $111.51 $385,379 1,023,775 D
Evans John M. CEO 2021-07-07 Sale −2,250 $112.62 $253,395 1,021,525 D
Derivatives
Evans John M. CEO 2021-07-07 Option exercise · Stock Option (Right to Buy −25,000 371,345 D
Open-market sales · 25,000 sh · avg $107.87 · $2,696,826
Loading xslF345X03/doc4.xml…